Share this article
NEW DELHI, Dec. 29, 2020 /PRNewswire/ Hindustan Syringes and Medical Devices (HMD), one of the top manufacturers of medical disposables worldwide, announced that it has ramped up production of its Kojak Auto Disable (AD) syringes in anticipation of a surge in demand for the coronavirus vaccine. AD syringes will be widely used for administering the eagerly awaited COVID-19 vaccine.
HMD, being one of the pioneers in the Indian healthcare industry, has left no stone unturned to help the government and the world fight the deadly disease. The organization is currently leading efforts to support COVID-19 vaccination in India and internationally, with production of the special Kojak Auto Disable (AD) syringes continuing on a war footing at its Faridabad plant. In fact, HMD has already produced 83.5 million Kojak Syringes as committed for the Indian Government. Considering the fact that the COVID-19 vaccine will soon be available, HMD have now shipped 140 Million Sy
VIETNAM NEWS DECEMBER 29
29/12/2020 16:54 GMT+7
HCM City to provide all public services online at level 4 by 2030
browser not support iframe.
Ho Chi Minh City has set a target to provide 100 percent of public services online at level 4 by 2030. Level 4 is the highest level of online public services, which allows users to fill and submit forms, and pay fees online.
In the first quarter of 2020, Ho Chi Minh City s authorities provided 668 online public administrative services at levels 3 and 4 in various fields, and more than 80 percent of local residents and organisations said they were satisfied with the services.
According to the city’s Department of Home Affairs, district and commune-level administrative units handled more than 84 million documents online in the last five years.
UNICEF names singer Yara regional ambassador for MENA - City Lights - Arts & Culture ahram.org.eg - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ahram.org.eg Daily Mail and Mail on Sunday newspapers.
COVAXX is currently conducting a Phase 1 clinical trial for the vaccine candidate.Aurobindo Pharma and US-based COVAXX have entered into an exclusive license agreement to develop, commercialize and manufacture UB-612, the first multitope peptide-based vaccine to fight COVID-19, for India and the United Nations Children s Fund (UNICEF) agency.
Under the signed agreement, Aurobindo Pharma has obtained the exclusive rights to develop, manufacture and sell COVAXX s UB-612 vaccine in India and to UNICEF, as well as non-exclusive rights in other select emerging and developing markets.
Aurobindo Pharma and COVAXX are partnering on clinical development, manufacturing and marketing of COVAXX s vaccine candidate, UB-612. The pharmaceutical company will manufacture the finished doses at its facilities in Hyderabad (Telangana). Aurobindo Pharma has the capacity of manufacturing 220 million doses in multi-dose presentation and is building additional facilities to have a total capacity of near
To develop and commercialize COVID-19 vaccine UB-612 for India and UNICEFAurobindo Pharma and COVAXX, a US-based company, have entered into an Exclusive License Agreement to develop, commercialize and manufacture UB-612, the first Multitope Peptide-based
Vaccine to fight COVID-19, for India and the United Nations Children s Fund (UNICEF) agency. COVAXX is currently conducting a Phase 1 clinical trial for the vaccine candidate.
Under the signed agreement, Aurobindo Pharma has obtained the exclusive rights to develop,
manufacture and sell COVAXX s UB-612 vaccine in India and to UNICEF, as well as non-exclusive rights in
other select emerging and developing markets. Aurobindo Pharma and COVAXX are partnering on clinical